In conclusion, the recent pharmaceutical model with oxfenicine inhibition of CPT-1 in mice and our previous Cpt1b+/− genetic mouse model studies support that CPT1b restriction is a good therapeutic approach against diet-induced insulin resistance. Here, CPT1B is linked to Insulin resistance.